Matches 1 - 50 out of 176 1 2 3 4 >
Match Document Document Title
7317017 A2B adenosine receptor antagonists  
Disclosed are novel A 2B adenosine receptor antagonists having the structure of Formula I or Formula II The compounds are particularly useful for treating asthma, inflammatory gastrointestinal...
7312243 Materials and methods for treatment of gastrointestinal disorders  
The subject invention pertains to materials and methods for the prevention and treatment of gastrointestinal diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative...
7312223 Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction  
The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure derivatives, and formulations thereof, and processes for...
7148229 Sulfonamide substituted xanthine derivatives  
The present invention is a sulfonamide substituted xanthine derivative of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is lower alkyl, lower alkyl substituted by phenyl,...
7135475 Amide substituted xanthine derivatives  
The present invention is a 1,3,8 substituted xanthine derivative of formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and R 3 are as defined in the specification. ...
7129239 Purine compounds and uses thereof  
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. ...
7115285 Composition and method for appetite and craving suppression and mood enhancement  
A composition for suppressing appetite and cravings for substances such as nicotine, coffee, sweets or chocolate while improving energy and enhancing mood comprises theobromine or a salt thereof at...
7101572 Taste masked aqueous liquid pharmaceutical composition  
A substantially taste masked liquid pharmaceutical composition containing a pharmaceutically effective amount of an unpleasant tasting drug dissolved or dispersed in an aqueous excipient base, said...
7098217 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands  
3,7-Dihydro-purine-2,6-dione derivatives of Formula (I) are provided wherein R 1 , R 2 , R 3 and R 4 are herein defined for use as CRF receptor ligands in the treatment of disorders...
7097859 Indium supplement compositions and methods therefor  
A tablet for oral administration of nutritional indium comprises about 10–50 mg indium sulfate, about 4–20 mg caffeine, about 2–10% by weight cocoa powder, and about 5–10% by weight ethyl...
7063865 Composition and method for substantially reducing the deleterious effects of alcohol on the body  
A composition that will substantially reduce the deleterious effects of alcohol on the body and substantially reduce the side effects associated with hangovers (i.e. headaches, dizziness, nausea,...
7019010 Combinations  
The present invention relates to a pharmaceutical composition, comprising (a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one of the active...
6979687 Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities  
The invention pertains to theophylline (1-methyl, 3-methyl xanthine) and IBMX (1-methyl, 3-isobutyl xanthine) derivatives of formulas I and II: where R 1 is —CH 3 or —CH 2 CH(CH 3 ) 2 ,...
6878715 Therapeutic compounds for inhibiting interleukin-12 signals and method for using same  
Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations...
6855736 Molecular target of neurotoxicity  
The present invention relates to the fields of biology, genetics and medicine. In particular it concerns new methods for the detection, characterization and/or treatment (or management) of neuro...
6815446 Selective antagonists of A2B adenosine receptors  
A compound of the following formula: wherein R is an aliphatic or cycloaliphatic amine group or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable salt thereof. The...
6790841 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents  
Compounds which are active against viruses have the following Formulas: wherein B is a purine or pyrimidine heterocyclic ring and is preferably selected from the group consisting of...
6734187 Purine derivatives and medicaments comprising the same as active ingredient  
Purine derivatives represented by the following formula and salts thereof: wherein R 1 represents a C 1 -C 4 alkyl group or difluoromethyl group; R 2 represents tetrahydrofuranyl group, a C 1...
6727259 Remedial agent for neural degeneration  
The present invention relates to a therapeutic agent for neurodegenerative disorders, comprising a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof...
6693106 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's)  
Pentoxifylline, pioglitazone and metformin have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproducts and crosslinks. The...
6693104 Theobromine with an anti-carcinogenic activity  
Disclosed is theobromine with an anti-carcinogenic activity which inhibits the suppression of GJIC (gap junctional intercellular communication), a pathological phenomenon occurring during...
6680323 Dihydropyrimidines and uses thereof  
This invention is directed to dihydropyrimidines which are selective antagonists for human α 1a receptors. This invention is also related to uses of these compounds for relaxing lower urinary...
6653312 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same  
Amidine compounds of the formula wherein the substituents are defined as in the application useful as NO-synthase enzyme inhibitors.
6649600 Adenosine receptor antagonists and methods of making and using the same  
The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be usefull...
6642243 Migraine medicine and method for treating same  
This invention is a safe and effective composition and method for treating acute migraine attacks using pseudoephedrine, acetaminophen, and other agents in an orally administrated form to alleviate...
6608069 Phenyl xanthine derivatives  
The present invention relates to novel compounds of formula (I): wherein Z represents a 5 or 6 membered cycloalkyl, aryl, substituted cycloalkyl, or substituted aryl, said cycloalkyl, aryl,...
6605600 Adenosine receptor antagonists and methods of making and using the same  
The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be useful...
6555545 Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver  
Hepatic cirrhosis and fibrosis and fatty liver can be prevented and treated by administering to a subject in need thereof an effective amount of at least one adenosine A 2A receptor antagonist or...
6545002 Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors  
The present invention provides compounds having the formula I: X is (C 1 -C 8 )alkylene, (C 2 -C 8 )alkenylene, (C 2 -C 8 )alkynylene, wherein one of the carbon atoms in the alkylene, alkenylene...
6472425 Methods for treating female sexual dysfunctions  
The present invention provides methods for treating female sexual dysfunctions by administering to a female individual a therapeutically effective amount of at least one compound that donates,...
6461591 Medical aerosol formulations  
A pressure-liquefied propellant mixture for aerosols, comprising a fluorinated alkane, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, and carbon dioxide, makes...
6365593 Methylxanthines in the diagnosis and treatment of autistic disorder  
The invention is based on the discovery that the levels of one or more methylxanthines in urine samples are significantly decreased in children diagnosed with symptoms of autistic disorder,...
6348470 Antitussive compositions  
The invention relates to the use of theobromine and/or its salts and/or its complexes optionally in admixture with other known active ingredients and inert solid or liquid carriers, additives and...
6337325 Combined preparation for the therapy of immune diseases  
A combination preparation comprising a compound which has a phosphodiesterase-inhibiting action, and a compound which reduces the biologically effective intracellular Ca 2+ content, is suitable...
6316457 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses  
Disclosed are nitrosated and/or nitrosylated phosphodiesterase inhibitors having the formula NO n -PDE inhibitor where n is 1 or 2. The invention also provides compositions comprising such...
6303619 Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors  
The invention concerns the use of a xanthine or a xanthine derivative having a meta-substituted acidic aryl at the 8-position to specifically modulate the physiologic role of adenosine activation...
6268373 Trisubstituted thioxanthines  
Disclosed is a compound selected from the group consisting of 1,3,8-triethyl-2,6-dithioxanthine; 1,3,8-triethyl-2-thioxanthine; 8-cyclopropyl-1-ethyl-3-(2-methyl-butyl)-6-thioxanthine;...
6258809 6-aryloxy and arylthiopurines  
Novel compounds and pharmaceutical compositions thereof, and methods of using same in treating anxiety, depression, and other psychiatric and neurological disorders. The novel compounds provided by...
6248746 3-(arylalkyl) xanthines  
With the above and other objects in view, the present invention comprises compounds having the general formula (I): ##STR1## wherein: R 1 is a C 2 -8 alkyl, C 2 -8 alkenyl, C 2 -8 alkynyl, C 3...
6221874 Method of treating bone loss by stimulation of calcitonin  
Compounds of the formula ##STR1## R 1 and R 2 are independently alkyl of 1 to 6 carbon atoms, allyl, or substituted allyl of 3 to 6 carbon atoms; R 3 is hydrogen, alkyl of 1 to 6 carbon atoms,...
6204245 Treatment of narcolepsy with immunosuppressants  
The invention provides compositions and methods for treatment of narcolepsy or isolated cataplexy. Such methods entail administering a therapeutically effective regime of at least one...
6187780 Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity  
Asymmetrically substituted xanthine derivatives having adenosine A 1 antagonistic activity. These are useful as pharmaceuticals. Exemplary are: (a)...
6127363 Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction  
A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type IV phosphodiesterase...
6117878 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors  
The invention concerns the use of 8-phenylxanthines, 8-cyloalkylxanthines or 8- substituted xanthine derivatives to specifically modulate the physiologic role of the A2B adenosine receptor.
6110923 Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity  
The present invention covers a method of treatment of cancer, in particular, colon carcinoma, comprising the step of administering the compound N2-(6-dimethylamino...
6090816 Aryl thioxanthines  
Disclosed are compounds having the formulae: ##STR1## wherein: Q 3 ,Q 6a ,Q 6b and Q 8 are independently a bond, C 1 -8 alkylene, C 2 -8 alkenylene and C 2 -6 alkynylene, and R 3 , R 6a , R 6b...
6083954 Method of treating cystic fibrosis  
The present invention provides a method of identifying CFTR-binding compounds for treating cells having a reduced apical Cl - conductance, such as cystic fibrosis cells. This identification method...
6060481 Method for improving insulin sensitivity using an adenosine receptor antagonist  
Methods for improving insulin sensitivity in a patient using one or more A 2B adenosine receptor antagonists are disclosed. These methods stimulate insulin dependent glucose uptake in muscle.
6025362 Uses of xanthine compounds  
Xanthine compounds are utilized to accelerate anesthetic recovery from the effects of certain compounds as propofol, etomidate, barbiturates, opioids, isoflurane, enflurane, halothane, desflurane,...
6025360 Use of theophylline for the manufacture of a medicament for the treatment of asthma  
A prophylactic treatment for the inflammatory condition associated with chronic asthma is disclosed comprising administering theophyline or pharmaceutically acceptable salts thereof to provide a...
Matches 1 - 50 out of 176 1 2 3 4 >